142 related articles for article (PubMed ID: 21545797)
1. The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent species.
Lu SX; Higgins GA; Hodgson RA; Hyde LA; Del Vecchio RA; Guthrie DH; Kazdoba T; McCool MF; Morgan CA; Bercovici A; Ho GD; Tulshian D; Parker EM; Hunter JC; Varty GB
Eur J Pharmacol; 2011 Jul; 661(1-3):63-71. PubMed ID: 21545797
[TBL] [Abstract][Full Text] [Related]
2. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).
Varty GB; Lu SX; Morgan CA; Cohen-Williams ME; Hodgson RA; Smith-Torhan A; Zhang H; Fawzi AB; Graziano MP; Ho GD; Matasi J; Tulshian D; Coffin VL; Carey GJ
J Pharmacol Exp Ther; 2008 Aug; 326(2):672-82. PubMed ID: 18492950
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species.
Varty GB; Hyde LA; Hodgson RA; Lu SX; McCool MF; Kazdoba TM; Del Vecchio RA; Guthrie DH; Pond AJ; Grzelak ME; Xu X; Korfmacher WA; Tulshian D; Parker EM; Higgins GA
Psychopharmacology (Berl); 2005 Oct; 182(1):132-43. PubMed ID: 16025321
[TBL] [Abstract][Full Text] [Related]
4. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.
McLeod RL; Tulshian DB; Bolser DC; Varty GB; Baptista M; Fernandez X; Parra LE; Zimmer JC; Erickson CH; Ho GD; Jia Y; Ng FW; Korfmacher W; Xu X; Veals J; Smith-Torhan A; Wainhaus S; Fawzi AB; Austin TM; van Heek M; Hey JA
Eur J Pharmacol; 2010 Mar; 630(1-3):112-20. PubMed ID: 20006596
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases.
Sobczak M; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Sałaga M; Storr M; Kordek R; Małecka-Panas E; Krajewska WM; Fichna J
J Pharmacol Exp Ther; 2014 Mar; 348(3):401-9. PubMed ID: 24345466
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3,5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl)piperidin-4-yl]-1H-benzimidazole, with anxiolytic potential.
Hirao A; Imai A; Sugie Y; Tamura T; Shimokawa H; Toide K
Eur J Pharmacol; 2008 Jan; 579(1-3):189-95. PubMed ID: 18001707
[TBL] [Abstract][Full Text] [Related]
8. Effect of a novel NOP receptor agonist (SCH 225288) on guinea pig irritant-evoked, feline mechanically induced and canine infectious tracheobronchitis cough.
McLeod RL; Tulshian DB; Ho GD; Fernandez X; Bolser DC; Parra LE; Zimmer JC; Erickson CH; Fawzi AB; Jayappa H; Lehr C; Erskine J; Smith-Torhan A; Zhang H; Hey JA
Pharmacology; 2009; 84(3):153-61. PubMed ID: 19696521
[TBL] [Abstract][Full Text] [Related]
9. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.
Jenck F; Wichmann J; Dautzenberg FM; Moreau JL; Ouagazzal AM; Martin JR; Lundstrom K; Cesura AM; Poli SM; Roever S; Kolczewski S; Adam G; Kilpatrick G
Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4938-43. PubMed ID: 10758169
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent.
Hirao A; Imai A; Sugie Y; Yamada Y; Hayashi S; Toide K
J Pharmacol Sci; 2008 Mar; 106(3):361-8. PubMed ID: 18319566
[TBL] [Abstract][Full Text] [Related]
11. Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS.
Fichna J; Sobczak M; Mokrowiecka A; Cygankiewicz AI; Zakrzewski PK; Cenac N; Sałaga M; Timmermans JP; Vergnolle N; Małecka-Panas E; Krajewska WM; Storr M
Neurogastroenterol Motil; 2014 Nov; 26(11):1539-50. PubMed ID: 25041572
[TBL] [Abstract][Full Text] [Related]
12. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
13. A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.
Zaveri NT; Marquez PV; Meyer ME; Polgar WE; Hamid A; Lutfy K
Alcohol Clin Exp Res; 2018 Feb; 42(2):461-471. PubMed ID: 29215139
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.
Gavioli EC; Calo' G
Naunyn Schmiedebergs Arch Pharmacol; 2006 Feb; 372(5):319-30. PubMed ID: 16491387
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic.
Yokoyama F; Yamauchi M; Oyama M; Okuma K; Onozawa K; Nagayama T; Shinei R; Ishikawa M; Sato Y; Kakui N
Psychopharmacology (Berl); 2009 Aug; 205(2):177-87. PubMed ID: 19357839
[TBL] [Abstract][Full Text] [Related]
16. Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.
Goeldner C; Spooren W; Wichmann J; Prinssen EP
Psychopharmacology (Berl); 2012 Jul; 222(2):203-14. PubMed ID: 22249359
[TBL] [Abstract][Full Text] [Related]
17. Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice.
Gavioli EC; Rizzi A; Marzola G; Zucchini S; Regoli D; Calo' G
Peptides; 2007 Jun; 28(6):1229-39. PubMed ID: 17499882
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of the nociceptin/orphanin FQ receptor on ethanol-mediated motivational effects in infant and adolescent rats.
Miranda-Morales RS; Pautassi RM
Behav Brain Res; 2016 Feb; 298(Pt A):88-96. PubMed ID: 25907741
[TBL] [Abstract][Full Text] [Related]
19. Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies.
Rizzi A; Molinari S; Marti M; Marzola G; Calo' G
Neuropharmacology; 2011 Mar; 60(4):572-9. PubMed ID: 21184763
[TBL] [Abstract][Full Text] [Related]
20. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
